Navigation Links
New guidelines set to improve standard of cows' milk allergy care
Date:9/20/2007

Liverpool, UK, 21 September 2007: New guidelines on the diagnosis and management of cows milk allergy (CMA), published today in the Archives of Disease in Childhood, are set to improve the standard of care of infants with CMA, the most common food allergy in children.1 The Guidelines for the Diagnosis and Management of Cows Milk Protein Allergy recommend only extensively hydrolysed (eHF) and amino acid-based formulas (AAF), and the Taskforces recommendations warn against the risks of soy and other mammalian milks, such as sheep and goat, in CMA management.

Drawn up by the independent international Taskforce of allergy experts Act Against Allergy, and supported by an educational grant from SHS International, a leader in the field of specialised clinical nutrition, the guidelines offer clear recommendations on how to diagnose and manage CMA as well as two algorithms one for breast-fed infants and one for formula-fed infants addressing all levels of disease severity.

These are the first practical guidelines on CMA diagnosis and management and are specifically aimed at primary care physicians and general paediatricians, says Professor Yvan Vandenplas, Paediatric Gastroenterologist at Vrije Universiteit Brussel, Brussels, Belgium and Chair of the Act Against Allergy Taskforce. Our recommendations will assist in establishing CMA diagnosis and level of severity, offering clear guidance on the recommended management at each stage, whilst debunking some of the misconceptions over the value of soy and other alternative milk sources in CMA.

In their paper, the Taskforce recommends against the use of soy, especially in infants under six months old, due to the risk of secondary intolerance which can be present in up to 60% of CMA infants.2 Alternative mammalian milks, such as sheep, buffalo, horse, camel or goat, present an even higher risk of cross-reactivity and are not recommended at all in CMA. Furthermore, milk substitutes based on grains, legumes or nuts, such as rice, oat, pea or almond milk, are to be avoided in infants and young children due to their poor nutritional profile. According to the Act Against Allergy Guidelines, the only milk alternatives recommended for the effective management of CMA are specialised hypoallergenic CMA formulas, namely eHFs and AAFs.

AAF is the only formula type recommended for all degrees of CMA severity (i.e. mild, moderate and severe). These formulas are based on amino acids, the building blocks of protein, which are considered virtually incapable of provoking an allergic reaction,3 while providing optimal nutrition for of the infant. Immediate usage of AAF is also recommended in infants with suspected CMA showing failure to thrive insufficient weight and/or length gain in order to rapidly stabilise the infants physical development.

In cases of mild to moderate, but not severe, CMA, the Taskforce advises that an eHF may be sufficient. When milk proteins are broken down (hydrolysed) into smaller fragments as happens in the production of eHFs their ability to provoke an allergic reaction is reduced. However, if symptoms do not improve sufficiently on an eHF, an AAF should be considered.

The SHS / Nutricia portfolio of hypoallergenic infant formulas is the only range of products that fully covers all degrees of CMA severity (i.e. mild to moderate and severe). The portfolio also includes the only AAF that is globally available and the most extensively clinically validated.

Jonathan Wogel, Global Allergy Director of SHS International says, SHS International and Nutricia have a long-standing heritage in the development the medical nutrition field, with over two decades experience in the production of specialised CMA formulas. To date however, there has been confusion over the diagnosis and usage of cows milk alternatives. We are proud to have been able to support the Act Against Allergy Taskforce in this initiative in order to finally set a clear protocol on CMA management and improve the quality of lives of infants with cows milk allergy and their families across the world.


'/>"/>

Contact: Claire Greeff
claire_greeff@uk.cohnwolfe.com
44-020-733-15382
Cohn & Wolfe, London
Source:Eurekalert

Related medicine news :

1. New CPR Guidelines issued by Heart Association
2. New guidelines for dealing with post traumatic stress disorder
3. New Guidelines Found To Benefit Cardiovascular Treatment
4. Healthy Feeding Guidelines for Children Ages 0 to 24 Months Issued
5. Fragile X-Associated Tremor /Ataxia Syndrome Need Guidelines For Diagnostic Tests
6. Government Organisation Proposes Strict Guidelines For SubStandard Medical Devices
7. FDA To Set New Guidelines To Revise Drug Companies Marketing Tactics
8. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
9. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
10. Guidelines for treatment of juvenile idiopathic arthritis formulated
11. Guidelines For Better Management Of Obsessive-Compulsive Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , ... February 23, 2017 , ... ... of Justice jointly issued a letter to withdraw previous guidance issued ... their gender identity. The guidance issued in May 2016 by the Obama Administration ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... with a clinician-based audience, will be participating in Rare Disease Day events, hosted ... D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Hamlin Dental Group ... that they are sponsoring a raffle. Throughout the month of February, patients who visit ... a gift card for a dinner for two at the Cheesecake Factory. , ...
(Date:2/23/2017)... Los Angeles, California (PRWEB) , ... February 23, ... ... for Global Sports Development will host a diverse symposium on “Doping ... School of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will ...
(Date:2/23/2017)... ... 23, 2017 , ... ERT, a global data and technology ... Research, a leading clinical development service provider, has selected ERT’s Trial Oversight suite ... in part to an array of circumstances including the use of multiple data ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 Nevro Corp. (NYSE: NVRO), a global medical ... treatment of chronic pain, today reported financial results for the ... 2016 Accomplishment & Highlights: Achieved ... increase of 228% as reported, over the prior year ... of 612% over the prior year International ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017 ... company focused on the development and commercialization of ... pain, announced that it will release fourth quarter ... Thursday, March 2nd, 2017. AcelRx management will host ... Time (1:30 p.m. Pacific Time) on March 2 ...
(Date:2/23/2017)... , Feb 23, 2017 ... Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... of around 1.8% over the next decade to reach approximately $12.8 billion ... estimates and forecasts for all the given segments on global as well ...
Breaking Medicine Technology: